Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tevimbra by BeiGene for Small-Cell Lung Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase III for Small-Cell Lung Cancer. According to GlobalData, Phase...
Tevimbra by BeiGene for Hepatocellular Carcinoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III...
Tevimbra by BeiGene for Glioblastoma Multiforme (GBM): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Tevimbra by BeiGene for Soft Tissue Sarcoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...
Tevimbra by BeiGene for Anaplastic Thyroid Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Anaplastic Thyroid Cancer. According to GlobalData, Phase...
Tevimbra by BeiGene for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...
Tevimbra by BeiGene for Mantle Cell Lymphoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
Tevimbra by BeiGene for Colon Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Colon Cancer. According to GlobalData, Phase II...
Tevimbra by BeiGene for Neuroendocrine Tumors: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II...
Tevimbra by BeiGene for Ureter Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase I for Ureter Cancer. According to GlobalData, Phase I...
Tevimbra by BeiGene for Bladder Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
Tevimbra by BeiGene for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase III for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...
Tevimbra by BeiGene for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Tevimbra by BeiGene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
Tevimbra by BeiGene for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Tevimbra by BeiGene for Metastatic Colorectal Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Tevimbra by BeiGene for Urethral Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase I for Urethral Cancer. According to GlobalData, Phase I...
Tevimbra by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Tevimbra by BeiGene for Thymic Carcinoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II...
Tevimbra by BeiGene for Follicular Lymphoma: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...